Search

… ProQR Announces Closing of Underwritten Public Offering of … and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated … of $6.50 per share. All of the shares were offered by ProQR. The closing included the full exercise of the …

… ProQR Strengthens its Scientific Advisory Board with the … SAB. Science is at the core of everything we do at ProQR, and with this group as our key advisors we can be more … of success that will be invaluable as we advance our R&D programs and our broader RNA technologies, including the …

… ProQR Announces Closing of Underwritten Public Offering of … and CAMBRIDGE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … securities laws of any such state or jurisdiction.  About ProQR ProQR Therapeutics is dedicated to changing lives …

… ProQR Announces Closing of Underwritten Public Offering of … share.  All of the shares are being offered by ProQR.  The closing included the full exercise of the … securities laws of any such state or jurisdiction.  About ProQR ProQR Therapeutics is dedicated to changing lives …

… ProQR Announces Clearance of IND Application to Start … affected by this devastating disease,“ said Noreen R. Henig, MD, Chief Medical Officer of ProQR. “Importantly, this trial is the first in ProQR’s …

… des médicaments accorde l’accès PRIME au Sepofarsen de ProQR pour l’amaurose congénitale de Leber 10 Cet accès … à soutenir une évaluation et une approbation accélérées ProQR estime que l'Union européenne représentera un marché … et CAMBRIDGE, Mass., 29 juill. 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq : PRQR), une entreprise dédiée …

… ProQR Announces Clearance of IND to Start Clinical Trial of … Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Investigational New Drug (IND) application for QR-1123. ProQR plans to start enrolling patients in a Phase 1/2 trial …

… ProQR to Present Top-Line Results from the Phase 1/2 Study of … Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … from the FDA as well as PRIME access by the EMA. About ProQR ProQR Therapeutics is dedicated to changing lives …

… ProQR Therapeutics and Yarrow Biotechnology, an RTW … sectors, and ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the … newly created by RTW, has in-licensed exclusive rights to ProQR’s antisense oligonucleotide technology (ASO) to develop …